TY - JOUR
T1 - Implementation of Continuous Glucose Monitoring in the Hospital
T2 - Emergent Considerations for Remote Glucose Monitoring During the COVID-19 Pandemic
AU - Galindo, Rodolfo J.
AU - Aleppo, Grazia
AU - Klonoff, David C.
AU - Spanakis, Elias K.
AU - Agarwal, Shivani
AU - Vellanki, Priya
AU - Olson, Darin E.
AU - Umpierrez, Guillermo E.
AU - Davis, Georgia M.
AU - Pasquel, Francisco J.
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: RJG is supported in part by NIH under Award Numbers 1K23DK123384-01 and P30DK11102. SA is supported in part by NIH under Award Numbers K23DK115896 and P30DK111022. EKS is partially supported by the VA MERIT award (#1I01CX001825) from the US Department of Veterans Affairs Clinical Sciences Research and Development Service. PV is supported in part by NIH grant 1K23DK113241. GEU is partly supported by research grants from the NIH/NATS UL1 TR002378 and 1P30DK111024-01. FJP is supported in part by NIH under Award Numbers 1K23GM128221-01A1 and P30DK111024.
Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RJG has received unrestricted research support to Emory for investigator-initiated studies from Novo Nordisk and consulting fees from Abbott Diabetes Care, Sanofi, Novo Nordisk, Eli Lilly, and Valeritas. GA has received research support from AstraZeneca, Dexcom, Eli Lilly, Insulet, Novo Nordisk, and is a consultant for Dexcom and Insulet. DCK is a consultant for Abbott, Ascensia, Dexcom, Eoflow, Fractyl, Lifecare, Novo, Roche, and Thirdwayv. EKS has received unrestricted research support from Dexcom (to Baltimore VA Medical Center and to University of Maryland) for the conduction of clinical trials. SA has nothing to disclose. PV has received consulting fees from Merck and Boehringer Ingelheim. DEO has nothing to disclose. GEU has received unrestricted research support from Sanofi, Novo Nordisk, and Dexcom. GM has nothing to disclose. FJP has received unrestricted research support from Merck and Dexcom and consulting fees from Merck, Boehringer Ingelheim, Sanofi, Lilly, and AstraZeneca. No other potential conflict of interest relevant to this article was reported. Because of the emerging nature of the current public health crisis related to COVID-19 this article is based only on the opinions of the authors. The suggestions should be considered as guidance only. This article is not intended to determine an absolute standard of medical care. Providers need to take into consideration the individual characteristics of each patient, assess their clinical condition, and decide the most appropriate monitoring and treatment plan. The contents do not represent the views of the U.S. Department of Veterans Affairs or the US Government.
Publisher Copyright:
© 2020 Diabetes Technology Society.
PY - 2020/7
Y1 - 2020/7
N2 - Continuous glucose monitoring (CGM) has become a widely used tool in the ambulatory setting for monitoring glucose levels, as well as detecting uncontrolled hyperglycemia, hypoglycemia, and glycemic variability. The accuracy of some CGM systems has recently improved to the point of manufacture with factory calibration and Food and Drug Administration clearance for nonadjunctive use to dose insulin. In this commentary, we analyze the answers to six questions about what is needed to bring CGM into the hospital as a reliable, safe, and effective tool. The evidence to date indicates that CGM offers promise as an effective tool for monitoring hospitalized patients. During the current coronavirus disease 2019 crisis, we hope to provide guidance to healthcare professionals, who are seeking to reduce exposure to SARS-Cov-2, as well as preserve invaluable personal protective equipment. In this commentary, we address who, what, where, when, why, and how CGM can be adopted for inpatient use.
AB - Continuous glucose monitoring (CGM) has become a widely used tool in the ambulatory setting for monitoring glucose levels, as well as detecting uncontrolled hyperglycemia, hypoglycemia, and glycemic variability. The accuracy of some CGM systems has recently improved to the point of manufacture with factory calibration and Food and Drug Administration clearance for nonadjunctive use to dose insulin. In this commentary, we analyze the answers to six questions about what is needed to bring CGM into the hospital as a reliable, safe, and effective tool. The evidence to date indicates that CGM offers promise as an effective tool for monitoring hospitalized patients. During the current coronavirus disease 2019 crisis, we hope to provide guidance to healthcare professionals, who are seeking to reduce exposure to SARS-Cov-2, as well as preserve invaluable personal protective equipment. In this commentary, we address who, what, where, when, why, and how CGM can be adopted for inpatient use.
KW - CGM
KW - COVID-19
KW - continuous glucose monitoring
KW - diabetes mellitus
KW - hospitalized
KW - inpatient
KW - type 2
UR - http://www.scopus.com/inward/record.url?scp=85087280533&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087280533&partnerID=8YFLogxK
U2 - 10.1177/1932296820932903
DO - 10.1177/1932296820932903
M3 - Comment/debate
C2 - 32536205
AN - SCOPUS:85087280533
SN - 1932-2968
VL - 14
SP - 822
EP - 832
JO - Journal of Diabetes Science and Technology
JF - Journal of Diabetes Science and Technology
IS - 4
ER -
